Identification

Name
Sulfadiazine
Accession Number
DB00359  (APRD00190)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. [PubChem]

Structure
Thumb
Synonyms
  • 2-sulfanilamidopyrimidine
  • 2-sulfanilylaminopyrimidine
  • 4-amino-N-2-pyrimidinylbenzenesulfonamide
  • N(1)-2-Pyrimidinylsulfanilamide
  • N(1)-2-Pyrimidylsulfanilamide
  • N1-2-pyrimidinylsulfanilamide
  • N1-2-pyrimidylsulfanilamide
  • Sulfadiazina
  • Sulfadiazine
  • Sulfadiazinum
  • Sulfapyrimidine
  • Sulphadiazine
Product Ingredients
IngredientUNIICASInChI Key
Sulfadiazine sodium84CS1P306F547-32-0JLDCNMJPBBKAHH-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Sulfadiazine Tab 7.7grTablet500.5 mgOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1957-12-312001-07-20Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SulfadiazineTablet500 mg/1OralEon Labs, Inc.1994-07-29Not applicableUs
SulfadiazineTablet500 mg/1OralRemedy Repack2013-02-112016-10-13Us
International/Other Brands
Adiazine
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Coptin Oral SuspensionSulfadiazine (41 mg) + Trimethoprim (9 mg)SuspensionOralAxcan Pharma1979-12-312006-09-12Canada
Coptin TabSulfadiazine (410 mg) + Trimethoprim (90 mg)TabletOralPfizer1979-12-311996-09-09Canada
Coptin TabSulfadiazine (410 mg) + Trimethoprim (90 mg)TabletOralAxcan Pharma1979-12-312006-09-12Canada
Ovoquinol ConesSulfadiazine (400 mg) + Diiodohydroxyquinoline (75 mg) + Undecylenic acid (50 mg)SuppositoryVaginalLab Nadeau LtÉe, Division Of Technilab Inc.1963-12-311999-09-28Canada
Ovoquinol Crm VaginaleSulfadiazine (8 %) + Diiodohydroxyquinoline (2 %) + Undecylenic acid (1 %)CreamVaginalLab Nadeau LtÉe, Division Of Technilab Inc.1980-12-311999-09-28Canada
Trisulfaminic SusSulfadiazine (167 mg) + Pyrilamine maleate (6.25 mg) + Pheniramine maleate (6.25 mg) + Phenylpropanolamine hydrochloride (12.5 mg) + Sulfamerazine (167 mg) + Sulfamethazine (167 mg)SuspensionOralShepherd Pharmaceuticals Inc.1959-12-312001-04-11Canada
Trisulfaminic TabSulfadiazine (167 mg) + Pyrilamine maleate (6.25 mg) + Pheniramine maleate (6.25 mg) + Phenylpropanolamine hydrochloride (12.5 mg) + Sulfamerazine (167 mg) + Sulfamethazine (167 mg)TabletOralShepherd Pharmaceuticals Inc.1959-12-312001-04-11Canada
Categories
UNII
0N7609K889
CAS number
68-35-9
Weight
Average: 250.277
Monoisotopic: 250.052446274
Chemical Formula
C10H10N4O2S
InChI Key
SEEPANYCNGTZFQ-UHFFFAOYSA-N
InChI
InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)
IUPAC Name
4-amino-N-(pyrimidin-2-yl)benzene-1-sulfonamide
SMILES
NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1

Pharmacology

Indication

For the treatment of rheumatic fever and meningococcal meningitis

Structured Indications
Pharmacodynamics

Sulfadiazine is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.

Mechanism of action

Sulfadiazine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. This enzyme is needed for the proper processing of para-aminobenzoic acid (PABA) which is essential for folic acid synthesis. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.

TargetActionsOrganism
ADihydropteroate synthetase
inhibitor
Plasmodium falciparum
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Sulfadiazine is excreted largely in the urine.

Half life
Not Available
Clearance
Not Available
Toxicity

Oral LD50 in mouse is 1500 mg/kg.

Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedione2,4-thiazolidinedione may increase the hypoglycemic activities of Sulfadiazine.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Sulfadiazine.Experimental
AbirateroneThe serum concentration of Sulfadiazine can be increased when it is combined with Abiraterone.Approved
AcarboseAcarbose may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Sulfadiazine.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Sulfadiazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Sulfadiazine.Approved
AcetohexamideAcetohexamide may increase the hypoglycemic activities of Sulfadiazine.Withdrawn
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Sulfadiazine.Approved, Vet Approved
AICA ribonucleotideAICA ribonucleotide may increase the hypoglycemic activities of Sulfadiazine.Experimental
AlaproclateAlaproclate may increase the hypoglycemic activities of Sulfadiazine.Experimental
AllicinAllicin may increase the hypoglycemic activities of Sulfadiazine.Investigational
AlogliptinAlogliptin may increase the hypoglycemic activities of Sulfadiazine.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Sulfadiazine.Approved, Withdrawn
AloxiprinAloxiprin may increase the hypoglycemic activities of Sulfadiazine.Experimental
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Sulfadiazine.Approved, Illicit, Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Sulfadiazine.Approved, Withdrawn
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Sulfadiazine.Approved
AmiodaroneThe metabolism of Sulfadiazine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Sulfadiazine.Approved
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Sulfadiazine.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Sulfadiazine.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Sulfadiazine.Approved
AprepitantThe serum concentration of Sulfadiazine can be increased when it is combined with Aprepitant.Approved, Investigational
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Sulfadiazine.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Sulfadiazine.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Sulfadiazine.Approved
AtazanavirThe metabolism of Sulfadiazine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Sulfadiazine can be decreased when combined with Atomoxetine.Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Sulfadiazine.Approved
BalaglitazoneBalaglitazone may increase the hypoglycemic activities of Sulfadiazine.Investigational
BalsalazideBalsalazide may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational
Bempedoic acidBempedoic acid may increase the hypoglycemic activities of Sulfadiazine.Investigational
BenmoxinBenmoxin may increase the hypoglycemic activities of Sulfadiazine.Withdrawn
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Sulfadiazine.Approved, Investigational
BoceprevirThe metabolism of Sulfadiazine can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Bortezomib can be decreased when combined with Sulfadiazine.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Sulfadiazine.Approved, Investigational
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Sulfadiazine.Approved, Investigational
BrofaromineBrofaromine may increase the hypoglycemic activities of Sulfadiazine.Experimental
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Sulfadiazine.Approved
BuforminBuformin may increase the hypoglycemic activities of Sulfadiazine.Withdrawn
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Sulfadiazine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Sulfadiazine.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Sulfadiazine.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Sulfadiazine.Approved
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Sulfadiazine.Approved
CandesartanThe metabolism of Candesartan can be decreased when combined with Sulfadiazine.Approved
CapecitabineThe metabolism of Sulfadiazine can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Sulfadiazine can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the hypoglycemic activities of Sulfadiazine.Experimental
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Sulfadiazine.Approved
CarbutamideCarbutamide may increase the hypoglycemic activities of Sulfadiazine.Experimental
CaroxazoneCaroxazone may increase the hypoglycemic activities of Sulfadiazine.Withdrawn
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Sulfadiazine.Approved, Investigational
CastanospermineCastanospermine may increase the hypoglycemic activities of Sulfadiazine.Experimental
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Sulfadiazine.Approved, Investigational
CeritinibThe serum concentration of Sulfadiazine can be increased when it is combined with Ceritinib.Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Sulfadiazine.Approved
CholecalciferolThe metabolism of Sulfadiazine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiglitazoneCiglitazone may increase the hypoglycemic activities of Sulfadiazine.Experimental
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Sulfadiazine.Approved
CinoxacinCinoxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Withdrawn
CisaprideThe metabolism of Cisapride can be decreased when combined with Sulfadiazine.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the hypoglycemic activities of Sulfadiazine.Approved
ClarithromycinThe metabolism of Sulfadiazine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Sulfadiazine can be decreased when combined with Clemastine.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Sulfadiazine.Approved, Nutraceutical
ClorindioneSulfadiazine may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Sulfadiazine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Sulfadiazine.Approved
CobicistatThe metabolism of Sulfadiazine can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Sulfadiazine can be increased when it is combined with Conivaptan.Approved, Investigational
CrisaboroleThe metabolism of Sulfadiazine can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Sulfadiazine can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Sulfadiazine.Approved, Investigational
CyclosporineSulfadiazine may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Sulfadiazine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Sulfadiazine can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Sulfadiazine.Approved
DapoxetineDapoxetine may increase the hypoglycemic activities of Sulfadiazine.Investigational
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Sulfadiazine.Approved, Investigational
DarunavirThe metabolism of Sulfadiazine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Sulfadiazine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Sulfadiazine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Sulfadiazine can be decreased when combined with Delavirdine.Approved
DeoxyspergualinDeoxyspergualin may increase the hypoglycemic activities of Sulfadiazine.Investigational
dersalazinedersalazine may increase the hypoglycemic activities of Sulfadiazine.Investigational
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Sulfadiazine.Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfadiazine.Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Sulfadiazine.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Sulfadiazine.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Sulfadiazine.Approved, Vet Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Sulfadiazine.Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Sulfadiazine.Approved
DihydroergotamineThe metabolism of Sulfadiazine can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Sulfadiazine.Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Sulfadiazine.Approved
DiphenadioneSulfadiazine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Sulfadiazine.Approved
DisopyramideDisopyramide may increase the hypoglycemic activities of Sulfadiazine.Approved
DoconexentThe metabolism of Doconexent can be decreased when combined with Sulfadiazine.Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Sulfadiazine.Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Sulfadiazine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Sulfadiazine.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Sulfadiazine.Approved
DosulepinThe metabolism of Sulfadiazine can be decreased when combined with Dosulepin.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Sulfadiazine.Approved
DoxycyclineThe metabolism of Sulfadiazine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Sulfadiazine.Approved, Illicit
DronedaroneThe metabolism of Sulfadiazine can be decreased when combined with Dronedarone.Approved
DulaglutideDulaglutide may increase the hypoglycemic activities of Sulfadiazine.Approved
DuloxetineDuloxetine may increase the hypoglycemic activities of Sulfadiazine.Approved
EfavirenzThe metabolism of Sulfadiazine can be decreased when combined with Efavirenz.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Sulfadiazine.Approved, Investigational
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Sulfadiazine.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Sulfadiazine.Approved
EnoxacinEnoxacin may increase the hypoglycemic activities of Sulfadiazine.Approved
EnzalutamideThe serum concentration of Sulfadiazine can be decreased when it is combined with Enzalutamide.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Sulfadiazine.Approved
ErythromycinThe metabolism of Sulfadiazine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramEscitalopram may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational
EstradiolThe metabolism of Estradiol can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Sulfadiazine.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Sulfadiazine.Approved
Ethyl biscoumacetateSulfadiazine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacThe metabolism of Etodolac can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
EtoperidoneEtoperidone may increase the hypoglycemic activities of Sulfadiazine.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Sulfadiazine.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Sulfadiazine.Approved
ExenatideExenatide may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational
FelodipineThe metabolism of Sulfadiazine can be decreased when combined with Felodipine.Approved, Investigational
FleroxacinFleroxacin may increase the hypoglycemic activities of Sulfadiazine.Approved
FloxuridineThe metabolism of Sulfadiazine can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Sulfadiazine can be decreased when combined with Fluconazole.Approved
FluindioneSulfadiazine may increase the anticoagulant activities of Fluindione.Investigational
FlumequineFlumequine may increase the hypoglycemic activities of Sulfadiazine.Withdrawn
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Sulfadiazine.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Sulfadiazine.Approved, Illicit
FluorouracilThe metabolism of Sulfadiazine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Sulfadiazine.Approved, Illicit
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Sulfadiazine.Approved, Investigational
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Sulfadiazine.Approved
FluvoxamineThe metabolism of Sulfadiazine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Sulfadiazine.Approved, Investigational
FosamprenavirThe metabolism of Sulfadiazine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Sulfadiazine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Sulfadiazine can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Sulfadiazine can be increased when it is combined with Fusidic Acid.Approved
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Sulfadiazine.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational
GavestinelThe metabolism of Gavestinel can be decreased when combined with Sulfadiazine.Investigational
GemfibrozilThe metabolism of Sulfadiazine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational
GlibornurideGlibornuride may increase the hypoglycemic activities of Sulfadiazine.Withdrawn
GliclazideThe metabolism of Gliclazide can be decreased when combined with Sulfadiazine.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Sulfadiazine.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Sulfadiazine.Approved
GliquidoneGliquidone may increase the hypoglycemic activities of Sulfadiazine.Approved
GlisoxepideSulfadiazine may increase the hypoglycemic activities of Glisoxepide.Approved
GLPG-0492GLPG-0492 may increase the hypoglycemic activities of Sulfadiazine.Investigational
GlyburideThe metabolism of Glyburide can be decreased when combined with Sulfadiazine.Approved
GrepafloxacinGrepafloxacin may increase the hypoglycemic activities of Sulfadiazine.Withdrawn
GuacetisalGuacetisal may increase the hypoglycemic activities of Sulfadiazine.Experimental
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Sulfadiazine.Approved, Investigational
GusperimusGusperimus may increase the hypoglycemic activities of Sulfadiazine.Investigational
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Sulfadiazine.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Sulfadiazine.Approved, Vet Approved
HarmalineHarmaline may increase the hypoglycemic activities of Sulfadiazine.Experimental
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the hypoglycemic activities of Sulfadiazine.Experimental
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Sulfadiazine.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Sulfadiazine.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Sulfadiazine.Experimental
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Sulfadiazine.Approved, Illicit
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Sulfadiazine.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Sulfadiazine.Approved
IdelalisibThe serum concentration of Sulfadiazine can be increased when it is combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Sulfadiazine.Approved
ImatinibThe metabolism of Imatinib can be decreased when combined with Sulfadiazine.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Sulfadiazine.Investigational, Withdrawn
IndinavirThe metabolism of Sulfadiazine can be decreased when combined with Indinavir.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Sulfadiazine.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Sulfadiazine.Approved, Investigational
Insulin AspartSulfadiazine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirSulfadiazine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Sulfadiazine.Approved
Insulin GlulisineSulfadiazine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanInsulin Human may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Sulfadiazine.Approved
Insulin PorkInsulin Pork may increase the hypoglycemic activities of Sulfadiazine.Approved
IproclozideIproclozide may increase the hypoglycemic activities of Sulfadiazine.Withdrawn
IproniazidIproniazid may increase the hypoglycemic activities of Sulfadiazine.Withdrawn
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Sulfadiazine.Approved, Investigational
IsavuconazoniumThe metabolism of Sulfadiazine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Sulfadiazine.Approved
IsoniazidThe metabolism of Sulfadiazine can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Sulfadiazine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Sulfadiazine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Sulfadiazine can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Sulfadiazine.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Sulfadiazine.Approved
KetoconazoleThe metabolism of Sulfadiazine can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Sulfadiazine.Approved, Vet Approved
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Sulfadiazine.Approved
LanreotideSulfadiazine may increase the hypoglycemic activities of Lanreotide.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Sulfadiazine.Approved, Investigational
LapatinibThe metabolism of Sulfadiazine can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Sulfadiazine.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Sulfadiazine.Approved
LevofloxacinLevofloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Sulfadiazine.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Sulfadiazine.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
LinagliptinLinagliptin may increase the hypoglycemic activities of Sulfadiazine.Approved
LiraglutideLiraglutide may increase the hypoglycemic activities of Sulfadiazine.Approved
LobeglitazoneThe metabolism of Sulfadiazine can be decreased when combined with Lobeglitazone.Approved
LopinavirThe metabolism of Sulfadiazine can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Sulfadiazine.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Sulfadiazine.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Sulfadiazine.Approved
LovastatinThe metabolism of Sulfadiazine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Sulfadiazine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Sulfadiazine can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Sulfadiazine.Approved, Investigational
ManidipineThe metabolism of Sulfadiazine can be decreased when combined with Manidipine.Approved
MebanazineMebanazine may increase the hypoglycemic activities of Sulfadiazine.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Sulfadiazine is combined with Mecamylamine.Approved
MecaserminSulfadiazine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Sulfadiazine.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Sulfadiazine.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Sulfadiazine.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Sulfadiazine.Investigational, Withdrawn
MesalazineMesalazine may increase the hypoglycemic activities of Sulfadiazine.Approved
MesteroloneMesterolone may increase the hypoglycemic activities of Sulfadiazine.Experimental
MestranolThe metabolism of Mestranol can be decreased when combined with Sulfadiazine.Approved
MetahexamideSulfadiazine may increase the hypoglycemic activities of Metahexamide.Experimental
MetforminMetformin may increase the hypoglycemic activities of Sulfadiazine.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Sulfadiazine.Approved
MethenamineThe risk or severity of adverse effects can be increased when Methenamine is combined with Sulfadiazine.Approved, Vet Approved
MethotrexateThe risk or severity of adverse effects can be increased when Sulfadiazine is combined with Methotrexate.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Sulfadiazine.Approved, Vet Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Sulfadiazine.Investigational
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Sulfadiazine.Approved
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Sulfadiazine.Approved
MidostaurinThe metabolism of Sulfadiazine can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Sulfadiazine can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolMiglitol may increase the hypoglycemic activities of Sulfadiazine.Approved
MiglustatMiglustat may increase the hypoglycemic activities of Sulfadiazine.Approved
MilnacipranMilnacipran may increase the hypoglycemic activities of Sulfadiazine.Approved
MinaprineMinaprine may increase the hypoglycemic activities of Sulfadiazine.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Sulfadiazine.Approved
MitiglinideMitiglinide may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational
MitotaneThe serum concentration of Sulfadiazine can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Sulfadiazine.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Sulfadiazine.Approved
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Sulfadiazine.Approved
NandroloneNandrolone may increase the hypoglycemic activities of Sulfadiazine.Experimental
NaproxenThe metabolism of Naproxen can be decreased when combined with Sulfadiazine.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Sulfadiazine.Approved, Investigational
NefazodoneThe metabolism of Sulfadiazine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Sulfadiazine can be decreased when combined with Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Sulfadiazine.Investigational
NetupitantThe serum concentration of Sulfadiazine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Sulfadiazine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypoglycemic activities of Sulfadiazine.Withdrawn
NicardipineThe metabolism of Sulfadiazine can be decreased when combined with Nicardipine.Approved
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Sulfadiazine.Approved, Vet Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Sulfadiazine.Approved
NilotinibThe metabolism of Sulfadiazine can be decreased when combined with Nilotinib.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Sulfadiazine.Approved
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Sulfadiazine.Investigational
NorfloxacinNorfloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Sulfadiazine.Approved
OctamoxinOctamoxin may increase the hypoglycemic activities of Sulfadiazine.Withdrawn
OctreotideOctreotide may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational
OlaparibThe metabolism of Sulfadiazine can be decreased when combined with Olaparib.Approved
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Sulfadiazine.Approved
OlsalazineOlsalazine may increase the hypoglycemic activities of Sulfadiazine.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Sulfadiazine.Approved
OsimertinibThe serum concentration of Sulfadiazine can be increased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Sulfadiazine.Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Sulfadiazine.Approved
Oxolinic acidOxolinic acid may increase the hypoglycemic activities of Sulfadiazine.Experimental
OxymetholoneOxymetholone may increase the hypoglycemic activities of Sulfadiazine.Approved, Illicit
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Sulfadiazine.Approved, Vet Approved
PalbociclibThe serum concentration of Sulfadiazine can be increased when it is combined with Palbociclib.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Sulfadiazine.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Sulfadiazine.Approved
PargylinePargyline may increase the hypoglycemic activities of Sulfadiazine.Approved
ParoxetineParoxetine may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational
PasireotideSulfadiazine may increase the hypoglycemic activities of Pasireotide.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Sulfadiazine.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Sulfadiazine.Approved
PentamidineSulfadiazine may increase the hypoglycemic activities of Pentamidine.Approved
PentobarbitalThe metabolism of Sulfadiazine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Sulfadiazine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Sulfadiazine.Withdrawn
PhenelzinePhenelzine may increase the hypoglycemic activities of Sulfadiazine.Approved
PhenforminPhenformin may increase the hypoglycemic activities of Sulfadiazine.Approved, Withdrawn
PhenindioneSulfadiazine may increase the anticoagulant activities of Phenindione.Approved
PheniprazinePheniprazine may increase the hypoglycemic activities of Sulfadiazine.Withdrawn
PhenobarbitalThe metabolism of Sulfadiazine can be increased when combined with Phenobarbital.Approved
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Sulfadiazine.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Sulfadiazine.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Sulfadiazine.Approved, Vet Approved
PhenytoinThe metabolism of Sulfadiazine can be increased when combined with Phenytoin.Approved, Vet Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Sulfadiazine.Approved, Investigational
Pipemidic acidPipemidic acid may increase the hypoglycemic activities of Sulfadiazine.Experimental
PirlindolePirlindole may increase the hypoglycemic activities of Sulfadiazine.Approved
Piromidic acidPiromidic acid may increase the hypoglycemic activities of Sulfadiazine.Experimental
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Sulfadiazine.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Sulfadiazine.Approved
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Sulfadiazine.Withdrawn
PosaconazoleThe metabolism of Sulfadiazine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintidePramlintide may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Sulfadiazine.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Sulfadiazine.Approved
PrilocaineThe risk or severity of adverse effects can be increased when Sulfadiazine is combined with Prilocaine.Approved
PrimidoneThe metabolism of Sulfadiazine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Procaine.Approved, Investigational, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Sulfadiazine.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Sulfadiazine.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Sulfadiazine.Investigational
PyrimethamineThe metabolism of Sulfadiazine can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Sulfadiazine.Approved, Illicit
QuinidineThe metabolism of Quinidine can be decreased when combined with Sulfadiazine.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Sulfadiazine.Approved
RabeprazoleThe metabolism of Sulfadiazine can be decreased when combined with Rabeprazole.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Sulfadiazine.Approved, Investigational
RanolazineThe metabolism of Sulfadiazine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypoglycemic activities of Sulfadiazine.Approved
RepaglinideSulfadiazine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RifabutinThe metabolism of Sulfadiazine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Sulfadiazine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Sulfadiazine can be increased when combined with Rifapentine.Approved
RitonavirThe metabolism of Sulfadiazine can be decreased when combined with Ritonavir.Approved, Investigational
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Sulfadiazine.Investigational, Withdrawn
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Sulfadiazine.Approved, Investigational
RosoxacinRosoxacin may increase the hypoglycemic activities of Sulfadiazine.Approved
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Sulfadiazine.Approved
RufloxacinRufloxacin may increase the hypoglycemic activities of Sulfadiazine.Experimental
RupatadineThe metabolism of Rupatadine can be decreased when combined with Sulfadiazine.Approved
SafrazineSafrazine may increase the hypoglycemic activities of Sulfadiazine.Withdrawn
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SaquinavirThe metabolism of Sulfadiazine can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Sulfadiazine.Approved
SecobarbitalThe metabolism of Sulfadiazine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Sulfadiazine.Approved
SertralineThe metabolism of Sertraline can be decreased when combined with Sulfadiazine.Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Sulfadiazine.Approved, Investigational
SiltuximabThe serum concentration of Sulfadiazine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Sulfadiazine can be increased when it is combined with Simeprevir.Approved
SitafloxacinSitafloxacin may increase the hypoglycemic activities of Sulfadiazine.Experimental
SitagliptinSitagliptin may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Sulfadiazine.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sulfadiazine is combined with Sodium Nitrite.Approved
SorafenibThe metabolism of Sulfadiazine can be decreased when combined with Sorafenib.Approved, Investigational
SotagliflozinSotagliflozin may increase the hypoglycemic activities of Sulfadiazine.Investigational
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved
St. John's WortThe serum concentration of Sulfadiazine can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololStanozolol may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
StiripentolThe serum concentration of Sulfadiazine can be increased when it is combined with Stiripentol.Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Sulfadiazine.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Sulfadiazine.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Sulfadiazine.Approved
SulfisoxazoleThe metabolism of Sulfisoxazole can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulodexideSulodexide may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational
SunitinibSulfadiazine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenThe metabolism of Suprofen can be decreased when combined with Sulfadiazine.Approved, Withdrawn
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Sulfadiazine.Approved
TapentadolThe metabolism of Tapentadol can be decreased when combined with Sulfadiazine.Approved
TelaprevirThe metabolism of Sulfadiazine can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Sulfadiazine can be decreased when combined with Telithromycin.Approved
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Sulfadiazine.Withdrawn
TemazepamThe metabolism of Temazepam can be decreased when combined with Sulfadiazine.Approved
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Sulfadiazine.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Sulfadiazine.Withdrawn
TeriflunomideThe metabolism of Sulfadiazine can be decreased when combined with Teriflunomide.Approved
TestosteroneThe metabolism of Testosterone can be decreased when combined with Sulfadiazine.Approved, Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Sulfadiazine.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Sulfadiazine.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Sulfadiazine.Approved, Vet Approved
TicagrelorThe metabolism of Sulfadiazine can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Sulfadiazine can be decreased when combined with Ticlopidine.Approved
TioclomarolSulfadiazine may increase the anticoagulant activities of Tioclomarol.Experimental
TocilizumabThe serum concentration of Sulfadiazine can be decreased when it is combined with Tocilizumab.Approved
TolazamideSulfadiazine may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideThe metabolism of Sulfadiazine can be decreased when combined with Tolbutamide.Approved
ToloxatoneToloxatone may increase the hypoglycemic activities of Sulfadiazine.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Sulfadiazine.Approved, Investigational
TopiroxostatThe metabolism of Sulfadiazine can be decreased when combined with Topiroxostat.Approved
TorasemideThe metabolism of Torasemide can be decreased when combined with Sulfadiazine.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Sulfadiazine.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Sulfadiazine.Experimental
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Sulfadiazine.Approved
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Sulfadiazine.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Sulfadiazine.Approved, Investigational, Nutraceutical
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Sulfadiazine.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Sulfadiazine.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Sulfadiazine.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Sulfadiazine.Withdrawn
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Withdrawn
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Sulfadiazine.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Sulfadiazine.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Sulfadiazine.Approved, Investigational
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Sulfadiazine.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Sulfadiazine.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Sulfadiazine.Investigational
VildagliptinVildagliptin may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Sulfadiazine.Approved
VogliboseVoglibose may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational
VoriconazoleThe metabolism of Sulfadiazine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Sulfadiazine.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Sulfadiazine.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Sulfadiazine.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Sulfadiazine.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Sulfadiazine.Approved
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Sulfadiazine.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Sulfadiazine.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Sulfadiazine.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hypoglycemic activities of Sulfadiazine.Withdrawn
ZiprasidoneThe metabolism of Sulfadiazine can be decreased when combined with Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Sulfadiazine.Approved
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Sulfadiazine.Approved
Food Interactions
Not Available

References

Synthesis Reference

Charles L. Fox, Jr., Shanta M. Modak, Paul Fox, "Wound dressing comprising silver sulfadiazine incorporated in animal tissue and method of preparation." U.S. Patent US4599226, issued September, 1977.

US4599226
General References
Not Available
External Links
Human Metabolome Database
HMDB14503
KEGG Drug
D00587
KEGG Compound
C07658
PubChem Compound
5215
PubChem Substance
46506164
ChemSpider
5026
BindingDB
50166571
ChEBI
9328
ChEMBL
CHEMBL439
Therapeutic Targets Database
DAP001238
PharmGKB
PA451539
Drugs.com
Drugs.com Drug Page
Wikipedia
Sulfadiazine
ATC Codes
J01EE06 — Sulfadiazine and tetroxoprimJ01EC02 — SulfadiazineJ01EE02 — Sulfadiazine and trimethoprimG01AE10 — Combinations of sulfonamides
MSDS
Download (73.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Toxoplasmosis, Cerebral1
3CompletedTreatmentToxoplasmosis, Congenital1
4RecruitingTreatmentToxoplasmosis1

Pharmacoeconomics

Manufacturers
  • Abbott laboratories pharmaceutical products div
  • Everylife
  • Impax laboratories inc
  • Lannett co inc
  • Lederle laboratories div american cyanamid co
  • Eli lilly and co
  • Sandoz inc
Packagers
Dosage forms
FormRouteStrength
SuspensionOral
TabletOral
SuppositoryVaginal
CreamVaginal
TabletOral500 mg/1
TabletOral500.5 mg
Prices
Unit descriptionCostUnit
Silver Sulfadiazine 1% Cream 400 gm Jar36.48USD jar
Silver Sulfadiazine 1% Cream 50 gm Jar21.99USD jar
Silver Sulfadiazine 1% Cream 85 gm Jar19.99USD jar
Silver Sulfadiazine 1% Cream 25 gm Jar13.99USD jar
Sulfadiazine 500 mg tablet2.5USD tablet
Sulfazine EC 500 mg Enteric Coated Tabs0.42USD tab
Sulfazine ec 500 mg tablet0.38USD tablet
Sulfazine 500 mg tablet0.25USD tablet
Sulfadiazine powder0.13USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)255.5 dec °CPhysProp
water solubility77 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-0.09HANSCH,C ET AL. (1995)
logS-3.51ADME Research, USCD
pKa6.36SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.601 mg/mLALOGPS
logP0.25ALOGPS
logP0.39ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)6.99ChemAxon
pKa (Strongest Basic)2.01ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area97.97 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity64.2 m3·mol-1ChemAxon
Polarizability24.39 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9877
Blood Brain Barrier+0.9383
Caco-2 permeable+0.6988
P-glycoprotein substrateNon-substrate0.9012
P-glycoprotein inhibitor INon-inhibitor0.913
P-glycoprotein inhibitor IINon-inhibitor0.9156
Renal organic cation transporterNon-inhibitor0.8437
CYP450 2C9 substrateNon-substrate0.8031
CYP450 2D6 substrateNon-substrate0.915
CYP450 3A4 substrateNon-substrate0.7671
CYP450 1A2 substrateNon-inhibitor0.9574
CYP450 2C9 inhibitorNon-inhibitor0.922
CYP450 2D6 inhibitorNon-inhibitor0.9548
CYP450 2C19 inhibitorNon-inhibitor0.9693
CYP450 3A4 inhibitorNon-inhibitor0.902
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8569
Ames testNon AMES toxic0.9206
CarcinogenicityNon-carcinogens0.9393
BiodegradationNot ready biodegradable0.9973
Rat acute toxicity1.8353 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9383
hERG inhibition (predictor II)Non-inhibitor0.8673
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.99 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0090000000-1bc83eabade65dc8953a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0910000000-bd163c77861c5a8afa49
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0900000000-260a572b5c7f3c070c26
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-052r-0900000000-580f983ba25c4cb3eb30
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-1900000000-8dc8c152ec6044f1c2e9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0090000000-23afa7ea3ef67a93a2e6
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0pb9-3960000000-355dcad6c59ae9c75fb7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-4900000000-337c5e4fc08cc648b85d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4l-8900000000-63cd0dba3c4894d64ae1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4l-9500000000-64c8a8332030e3f700a1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05mo-9300000000-746250effd08ec8bf51b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0090000000-e8005ac37727f1c540d8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0pb9-2960000000-ff127258fb7c09ae3665
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-4900000000-4fa5b350b17254bc9a1a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4l-8900000000-4a998ad7772889643c1f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4l-9500000000-7e0d8190b4e7f7ced956
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05mo-9300000000-9cca42d677a6ef782a2c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-1900000000-4b5c2f7e29a6399f475c

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonamides
Direct Parent
Aminobenzenesulfonamides
Alternative Parents
Benzenesulfonyl compounds / Aniline and substituted anilines / Pyrimidines and pyrimidine derivatives / Organosulfonamides / Heteroaromatic compounds / Aminosulfonyl compounds / Azacyclic compounds / Primary amines / Organopnictogen compounds / Organic oxides
show 1 more
Substituents
Aminobenzenesulfonamide / Benzenesulfonyl group / Aniline or substituted anilines / Pyrimidine / Organosulfonic acid amide / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Heteroaromatic compound / Aminosulfonyl compound / Sulfonyl
show 12 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
substituted aniline, sulfonamide, pyrimidines, sulfonamide antibiotic (CHEBI:9328)

Targets

Kind
Protein
Organism
Plasmodium falciparum
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dihydropteroate synthase activity
Specific Function
Not Available
Gene Name
Not Available
Uniprot ID
Q27738
Uniprot Name
Dihydropteroate synthetase
Molecular Weight
43370.845 Da
References
  1. de Araujo MV, Vieira EK, Silva Lazaro G, Conegero LS, Almeida LE, Barreto LS, da Costa NB Jr, Gimenez IF: Sulfadiazine/hydroxypropyl-beta-cyclodextrin host-guest system: Characterization, phase-solubility and molecular modeling. Bioorg Med Chem. 2008 May 15;16(10):5788-94. doi: 10.1016/j.bmc.2008.03.057. Epub 2008 Mar 27. [PubMed:18434167]
  2. Iliades P, Meshnick SR, Macreadie IG: Mutations in the Pneumocystis jirovecii DHPS gene confer cross-resistance to sulfa drugs. Antimicrob Agents Chemother. 2005 Feb;49(2):741-8. [PubMed:15673759]
  3. Prabhu V, Lui H, King J: Arabidopsis dihydropteroate synthase: general properties and inhibition by reaction product and sulfonamides. Phytochemistry. 1997 May;45(1):23-7. [PubMed:9127492]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:35